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Abstract
In cancer, many genes are mutated by genome rearrangement, but our understanding of the functional consequences of this 
remains rudimentary. Here we report the F-box protein encoded by FBXL17 is disrupted in the region of the gene that encodes 
its substrate-binding leucine rich repeat (LRR) domain. Truncating Fbxl17 LRRs impaired its association with the other 
SCF holoenzyme subunits Skp1, Cul1 and Rbx1, and decreased ubiquitination activity. Loss of the LRRs also differentially 
affected Fbxl17 binding to its targets. Thus, genomic rearrangements in FBXL17 are likely to disrupt  SCFFbxl17-regulated 
networks in cancer cells. To investigate the functional effect of these rearrangements, we performed a yeast two-hybrid screen 
to identify Fbxl17-interacting proteins. Among the 37 binding partners Uap1, an enzyme involved in O-GlcNAcylation of 
proteins was identified most frequently. We demonstrate that Fbxl17 binds to UAP1 directly and inhibits its phosphorylation, 
which we propose regulates UAP1 activity. Knockdown of Fbxl17 expression elevated O-GlcNAcylation in breast cancer 
cells, arguing for a functional role for Fbxl17 in this metabolic pathway.
Keywords FBXL17 · Genome rearrangements · O-GlcNAcylation · O-GlcNAc · UAP1 · Ubiquitin · Phosphorylation · 
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Introduction
The genomes of most common epithelial cancers, such as 
breast cancer, are highly rearranged, but our knowledge of 
the rearrangements and the genes they target remains rudi-
mentary [1]. A few common, large-scale rearrangements 
have been known for some time, such as loss of the distal 
arm of 8p, 17p and 18q and the amplification of ERBB2 
in breast cancer, but many more less-frequently occurring 
aberrations remain to be characterised and may be diagnosti-
cally or therapeutically important. For example, the EML4-
ALK fusion occurs in only approximately 5% of non-small 
cell lung cancers and is a target for therapy [2]. Genome 
sequencing has focused on point mutations in exomes, with 
only a few results for structural mutations reported so far, 
for limited sets of tumours [3–8]. Array-CGH detects larger 
scale unbalanced rearrangements and is available for large 
panels of tumours [9]. If such breaks fall within genes, they 
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must at least inactivate that copy of the gene, and in some 
cases they will create truncated proteins or gene fusions. 
Some gene fusion data are also available, from genomic 
[3–8] or transcript sequencing [10]. From surveying these 
datasets, we determined that FBXL17 is among the more fre-
quently rearranged genes in a number of epithelial cancers, 
including breast, prostate and oesophageal cancers.
FBXL17 encodes a little-studied member of the F-box 
family of proteins (FBPs). They are components of the ubiq-
uitin conjugation pathway, which, by directing the ubiquit-
ination of target proteins, regulate major cellular processes 
that require rapid alterations in protein levels, activity and 
localisation, such as cell cycle progression, cell signalling, 
and receptor recycling [11]. Ubiquitination of proteins 
requires an enzymatic cascade involving an E1 ubiquitin-
activating enzyme, an E2 ubiquitin-conjugating enzyme, and 
an E3 ubiquitin ligase [12]. FBPs are subunits of the SCF 
(Skp1-Cul1-F-box protein)-type E3 ubiquitin ligases, which 
utilise protein–protein interaction domains, like leucine-rich 
or WD40 repeats, to recruit substrates to the ligase. FBPs 
bind an adaptor protein Skp1 through their F-box domains 
(FBD), and the FBP:Skp1 dimer is a switchable unit that 
docks with a cullin scaffold and Rbx1 (Ring finger domain 
containing protein), which in turn recruits a ubiquitin-
charged E2 ligase. The Cand1 protein actively dissociates 
the pool of FBP:Skp1 dimers from cullin, regulating the lev-
els of active E3 ligases in the cell [13, 14]. FBPs not engaged 
as part of active E3 ligases also have functions outside of the 
Ubiquitin Proteasome System (UPS) [15].
Several FBPs have oncogenic and/or tumour suppressive 
activities [16, 17]. Indeed, the first FBP described, Skp2 
(S-phase kinase-associated protein 2, Fbxl1) is activated 
by amplification in several cancers, including breast, lym-
phoma, non-small cell lung cancer and glioblastoma [18, 
19]. Skp2 is thought to have its main oncogenic activity by 
promoting the degradation of the cyclin-dependent kinase 
inhibitor, p27 [20–22]. However, loss of SKP2 also induces 
senescence in response to oncogenic stimuli, such as Ras 
expression or the loss of Pten [23]. Fbxw7 is a tumour sup-
pressor, inactivated in approximately 7% cancers [24], which 
targets the turnover of important oncogenes, such as Myc, 
cyclin E, and Notch [16]. β-TrCP (BTRC , Fbxw11) is also 
mutated in several cancers, including breast and colorectal 
cancer and melanoma, potentially stabilising its oncogenic 
substrate β-catenin [19]. The true extent of FBP dysregula-
tion in cancer, particularly through genomic rearrangements, 
is unknown. We found FBXL17 is rearranged in breast can-
cers, and these rearrangements often disrupt the LRRs of 
Fbxl17. Loss of LRRs leads to a differential loss of interac-
tion with Fbxl17 binding partners, and prevents its assembly 
into a functional SCF complex. We show that Fbxl17 inter-
acts with Uap1, UDP-N-acetylglucosamine pyrophosphory-
lase 1, to regulate the overall levels of N-acetylglucosamine 
modification (O-GlcNAcylation) of proteins in cells. Our 
data support a model whereby Fbxl17 has tumour suppressor 
activity in breast cancers.
Results
FBXL17 is rearranged in cancer
To identify genes that are rearranged in breast cancers, 
we scanned segmented array-CGH copy number data for 
1992 primary breast tumours [9]. 135 (7%) had at least one 
genomic break within FBXL17, detected as a copy number 
step, distributed in various ways (Fig. 1a). The majority of 
these copy number losses or gains occurred at the 3′ end 
of FBXL17. Given the LRRs of Fbxl17 are encoded from 
exon 3 onwards it is likely these protein–protein interacting 
domains are disrupted by such rearrangements.
In addition to breaks in tumours, array-CGH data showed 
breaks in FBXL17 in four cancer cell lines, the breast car-
cinoma cell lines, BT-474, HCC38, and HCC1395, and the 
oesophageal/gastric cardia adenocarcinoma line OE-19 
[25]. The breaks were verified by FISH (Figs. 1b and S1). 
In BT-474, one of three copies of FBXL17 was broken, 
with retention of the 3′ end, exons 7–9 (Figs. 1b and S1B). 
Both HCC38 and OE-19 had an extra copy of the 5′ end of 
FBXL17, up to intron 1 and intron 7, respectively (Figs. 1b 
and S1B). In HCC38, this break was confirmed to be the 
FBXL17-PJA2 fusion transcript reported in [10] (Fig. S1C, 
S1F and S1G). In HCC1395, both array-CGH (Fig. S1H) 
and paired-end sequencing showed an internal homozygous 
deletion in FBXL17 between exons 6 and 9 [5, 25] verified 
by RT-PCR and FISH (Fig. S1D, S1E and S1I) which would 
truncate Fbxl17 near its C-terminus and encode a mutant 
protein lacking approximately three LRRs (Fig. 1b).
Because the cell line examples may not be typical, we 
looked for examples of FBXL17 rearrangements in breast 
cancers, in paired-end whole-genome DNA sequencing 
Fig. 1  Breaks in FBXL17 and the proteins encoded. a Breaks in 
135/1992 breast tumours [9], detected as copy number steps by 
array-CGH. X-axis is genomic sequence of FBXL17, reversed 
since FBXL17 is a negative strand gene. Each horizontal line repre-
sents a tumour, with breaks indicated by colour change. Blue, copy 
number loss; white, no change; red, gain. b FBXL17 exons from 
Ensembl transcript ENST00000542267.5 (Refseq NM_001163315.2, 
NP_001156787.2), chr5:107,859,045-108,382,098 in GRCh38/hg38. 
Triangles indicate breakpoints in FBXL17 identified in cell lines (as 
labelled) or primary breast tumours (unlabelled), Asterisk indicates 
known fusion. Bottom, protein domains of Fbxl17 scaled to protein 
sequence. L, leucine-rich repeat. c Non-synonymous somatic muta-
tions mapped to Fbxl17 as reported by The Cancer Genome Atlas 
(TCGA), arrows indicate breast cancer associated mutations. Sche-
matic underneath represents Fbxl17 domains, green, N-terminus, pur-
ple, F-box domain, red, leucine-rich repeats
◂
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data from 250 primary breast tumours of the Cambridge 
Personalised Breast Cancer Programme. Rearrangements 
(‘Structural variants’) in FBXL17 were identified in five of 
the tumours. Manual inspection of RNA sequences from 
these five tumours confirmed that two of the rearrange-
ments were transcribed as predicted: a translocation joining 
exon 6 to an undocumented exon on chromosome 7 and a 
duplication of exon 6, respectively (Fig. 1b; Supplementary 
Table 1). A third case with a breakpoint in intron 6 showed 
unspliced transcription from exon 6 into intron 7; however, 
we cannot rule out that this was normal unspliced RNA. 
Serendipitously, a further RNA sample, inspected because 
it had a rearrangement which did not pass filtering, showed 
splicing from exon 6 into exon 4. This suggested the pres-
ence of a rearrangement which was not detected by DNA 
sequencing in an additional tumour. The partial agreement 
we find between RNA and DNA sequencing is expected as 
both methods lack sensitivity to identify all rearrangements 
[26]. Thus, consistent with the cell line rearrangements, the 
breakpoints in the tumours fell within introns that would dis-
rupt the expression of LRRs, with the majority (4/6) occur-
ring in intron 6 (Fig. 1b, Supplementary Table 1). There 
was no clear relationship between FBXL17 rearrangement 
and any molecular classification [27] of the tumours and cell 
lines, although five of the six tumours and the breast cell 
lines were TP53 mutant (Supplementary Table 1). Of the 
tumours, three were oestrogen receptor (ER) positive, and 
three were ER-negative. One tumour and one cell line were 
ERBB2/HER2 positive. We also classified these tumours 
into the 11 IntClust sets [27], and they fell into three sets: 
clusters 4, 7 and 10. In addition, classifying these six cases 
using PAM50 breast cancer subtyping, gave four basal and 
two luminal A cases. Although the number of cases is small, 
these data suggest Fbxl17 is not rearranged in a particular 
cancer subtype.
Rearrangements of FBXL17 have also been detected in 
other epithelial cancers (Supplementary Table 2) including 
prostate [8] and oesophageal adenocarcinoma [7]. Many of 
these rearrangements are also predicted to truncate Fbxl17, 
resulting in loss of LRRs. TCGA (Cancer Genome Atlas 
project) data was mined for genomic alterations affecting 
FBXL17 using cBioPortal (http://cbiop ortal .org) [28]. Per-
haps most striking was the TCGA mapping of non-synon-
ymous somatic FBXL17 mutations. Mutations in FBXL17 
almost exclusively (68/70) target its C-terminus containing 
the FBD and LRRs (Fig. 1c).
In summary, FBXL17 is broken in approximately 7% of 
breast cancers, and additionally rearranged or mutated in 
other epithelial cancers. At least some of the breaks truncate 
Fbxl17, removing some or all of the LRRs and sometimes 
also the FBD. Examples of truncation are present in three 
cancer cell lines, and rearrangements have been confirmed in 
primary breast tumours. These genomic alterations suggest 
the ability of Fbxl17 to recruit substrates for ubiquitination 
or to form part of an SCF complex may be compromised.
Deletion of LRRs in Fbxl17 compromises 
ubiquitination activity due to impaired recruitment 
of SCF subunits
As most of the genomic rearrangements in FBXL17 are 
predicted to target its LRRs, we wanted to investigate the 
effect of their loss on Fbxl17 ligase activity. We used co-
immunoprecipitation assays to check the incorporation 
of Fbxl17 into an SCF E3 ligase. HEK293T cells were 
co-transfected with the subunits of SCF ligases, Skp1, 
Cullin1, Rbx1, and various N-terminally FLAG-tagged 
Fbxl17 constructs (full-length Fbxl17 (1-701aa), an inter-
nal FBD deletion, Fbxl17ΔFbox (Δ324-358aa) and two 
LRR-truncation constructs Fbxl17∆3LRR (1-586aa), and 
Fbxl17∆10LRR (1-384aa) (Fig. 2a). 48 h post transfec-
tion, cells were lysed, immunoprecipitated with FLAG 
antibodies, and blotted for the associated SCF subunits 
(Figs. 2b and S2B). While Skp1, Rbx1 and Cullin1 co-
immunoprecipitated efficiently with WT Fbxl17, these 
components were reduced in the immunoprecipitates of 
the truncation mutants. For example, Cullin1 binding to 
Fbxl17Δ3LRR was reduced by 81% (p = 4.12E−04; n = 4) 
and Fbxl17Δ10LRR by 82% (p = 1.28E−06; n = 4) relative 
to WT Fbxl17, while Skp1 binding to Fbxl17Δ3LRR was 
reduced by 77% (p = 5.52E−05; n = 5) and Fbxl17Δ10LRR 
by 67% (p = 2.74E−05; n = 4) relative to WT Fbxl17, despite 
these truncations having intact FBDs (Figs. 2b and S2B). As 
expected, when the FBD was deleted in Fbxl17ΔFbox, none 
of the subunits were co-immunoprecipitated. These data 
indicate that in addition to the FBD, the LRRs of Fbxl17 
facilitate the assembly of the  SCFFbxl17 ligase.
Fig. 2  Loss of Fbxl17 LRRs impairs recruitment of  SCFFbxl17 subu-
nits and  SCFFbxl17 ligase activity. a Schematic showing Fbxl17 con-
structs used to make SCF ligases, all contain an N-terminal FLAG 
tag (not shown). L, leucine-rich repeat. b A representative immunob-
lot for SCF holoenzyme components that co-immunoprecipitate with 
FLAG-Fbxl17 and mutant Fbxl17 constructs FLAG-Fbxl17ΔFbox, 
FLAG-Fbxl17Δ3LRR and Fbxl17Δ10LRR, n = 4. c Titration of the 
auto-ubiquitination activity of purified  SCFFbxl17 ligase complexes. A 
concentration gradient (12.5  nM, 25  nM, 50  nM, 100  nM) of puri-
fied  SCFFbxl17 or mutant complexes  SCFFbxl17ΔFbox,  SCFFbxl17Δ3LRR 
or  SCFFbxl17Δ10LRR was used in an in  vitro ubiquitination assay in 
the presence of a ubiquitin mix (ubiquitin buffer, UBE1, UbcH5a 
and ATP). Following SDS-PAGE membranes were probed with 
anti-FLAG antibody to detect  SCFFbxl17 ligases, n = 2. d As (C) but 
probed with anti-ubiquitin antibody, n = 2. e In  vitro ubiquitination 
assay of  SCFFbxl17 and mutant ligase complexes in combination with 
HA-tagged substrate Sufu in the presence of a ubiquitin mix as in c. 
Proteins resolved by SDS-PAGE and membrane probed with anti-HA 
antibody, n = 3
◂
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Since the Cullin1 and Rbx1 subunit allow E2 recruitment, 
these data suggest that the mutant  SCFFbxl17 ligases will have 
reduced activity. We tested this by performing in vitro ubiq-
uitination assays of purified SCF complexes, assembled with 
either WT or LRR-truncated Fbxl17 proteins, in the pres-
ence of an E1 and E2 enzyme. We first tested the ability of 
the mutant Fbxl17 proteins to promote auto-ubiquitination as 
part of an SCF E3 ligase (Figs. 2c, d and S2A). We observed 
higher molecular weight bands using an antibody raised 
against Fbxl17 using 25 nM of  SCFFbxl17 in in vitro ubiqui-
tination reactions, and the signal intensified with increasing 
concentrations of the WT ligase. In parallel assays, 50 nM of 
mutant  SCFFbxl17∆3LRR ligase showed residual activity which 
increased at 100 nM, but it was considerably less than WT 
 SCFFbxl17 ligase.  SCFFbxl17Δ10LRR ligase showed the greatest 
reduction in activity (Fig. 2c), comparable to the inactive 
 SCFFbxl17ΔFbox mutant. The difference in activity of the SCF 
complexes was even more apparent when the membranes 
were probed for ubiquitin (Fig. 2d).  SCFFbxl17ΔFbox had no 
ligase activity, while E3 ubiquitin ligases made with the 
LRR-truncated Fbxl17 mutants had reduced ligase activity 
compared to WT Fbxl17.
To test whether the ligases made by WT or mutant ver-
sions of Fbxl17 could ubiquitinate a heterologous substrate, 
we performed in vitro ubiquitination assays using Sufu 
(Fig. 2e) [29]. HA-Sufu was purified from HEK293T cells 
by immunoprecipitation. High molecular weight smears can 
be seen after the addition of  SCFFbxl17 (Fig. 2e, lane 4) and to 
a much lesser extent  SCFFbxl17Δ3LRR (Fig. 2e, lane 6). Both 
 SCFFbxl17ΔFbox and  SCFFbxl17Δ10LRR show greatly reduced 
ubiquitination activity. Together these data indicate that the 
LRRs in Fbxl17 contribute to assembly of the SCF E3 ligase 
and its ligase activity.
Fbxl17 interacting proteins identified by yeast‑two 
hybrid screening
Our data suggest that if Fbxl17 is mutated in the LRR-
encoding region, the proteins interacting with them will be 
mis-regulated as a result of aberrant SCF assembly and its 
effects on ligase activity. We performed a yeast two-hybrid 
screen to identify Fbxl17 interacting partners. To focus 
the screen on LRR-binding partners, we engineered the 
bait plasmid to contain the FBD and LRRs (321-701aa) of 
Fbxl17 but omitted its N-terminus. 37 unique prey, cloned 
in-frame to the Gal4 activation domain (GAD), were identi-
fied as candidate partners for Fbxl17 (Table 1; Fig. S3A). 
More than a third (13/37) of the prey were isolated inde-
pendently at least twice. The most common prey plasmids 
isolated encoded GAD fusions to UDP-N-acetylglucosamine 
pyrophosphorylase 1 (Uap1) and to ubiquitin-fold modifier 
conjugating enzyme 1 (Ufc1), which were isolated 26 and 13 
times, respectively. Moreover, since multiple, non-identical 
plasmids were isolated, a minimal common region defined 
a likely interacting domain within it, e.g. aa 357-505 at the 
C-terminus of Uap1 (Table 1). Additionally, Klhl12 and 
Klhl7, two members of the Kelch-like family of proteins, 
casein kinase 2b (Csnk2B), rearranged L-Myc fusion (Rlf), 
and C21orf91 were repeatedly isolated. To test whether the 
interaction between Fbxl17 and its prey was dependent on 
its LRRs, three LRRs (Δ3LRR) were deleted from the bait 
plasmid. Although this truncation did not affect Fbxl17 
expression (Fig. S3B), none of the yeast co-transformed with 
the Δ3LRR bait plasmid and the various prey grew under 
the selective conditions requiring a bait-prey interaction. 
These results indicated Fbxl17 interaction with its prey was 
dependent on its three C-terminal LRRs (Fig. S3A).
Fbxl17 interacts with Uap1, Ufc1, Klhl12 and Csnk2B 
in human cells in vivo
To validate the yeast two-hybrid results, we tested Uap1, 
Ufc1, Csnk2B and Klhl12 for their interaction with Fbxl17 
in human cells, using co-immunoprecipitation assays. All 
four proteins tested were detected in immunoprecipitates 
of FLAG-tagged Fbxl17 (Fig. 3a–d). We noted truncation 
of LRRs resulted in increased expression of mutant Fbxl17 
(Fig. 2b–d). Despite their enhanced expression, Klhl12 did 
not interact with either the ∆3LRR or ∆10LRR mutants, 
indicating its interaction with Fbxl17 was dependent on the 
LRRs (Fig. 3a). Uap1 and Ufc1 both co-immunoprecipitated 
with WT and ∆3LRR Fbxl17, but truncation of 10 LRRs 
ablated their interaction (Fig. 3b, c). Uap1 was also present 
in immunoprecipitates of the mutant FLAG-Fbxl17∆Fbox 
indicating that Uap1 binding is dependent on LRR2-8 in 
Fbxl17 (Fig. S3C). In contrast to the other partner proteins, 
HA-Csnk2B co-immunoprecipitated roughly equivalently 
with WT, ∆3LRR, and ∆10LRR constructs, suggesting 
that their interaction does not rely on the LRRs and thus 
may interact via the FBD or N-terminus of Fbxl17 in human 
cells (Fig. 3d).
The diminished interactions of truncated Fbxl17 with 
some of its binding partners could be caused by a change 
in its subcellular distribution. Cellular fractionation and 
immunofluorescence assays were conducted in parallel to 
determine the distribution of the WT and mutant proteins in 
cells. Endogenous Fbxl17 was present in both cytoplasmic 
and nuclear fractions (Figs. S3D, S4A). Immunofluores-
cence showed all transfected Fbxl17 constructs showed a 
predominantly nuclear localisation and also weaker cyto-
plasmic staining (Fig. S4A). This argues against an altered 
localisation preventing the mutant forms from interacting 
with its binding partners.
In sum, these data validate results from the yeast two-
hybrid screen since the binding partners identified also 
interact in human cells with the full length Fbxl17 protein. 
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Furthermore, the association of Klhl12, Ufc1, and Uap1 
with Fbxl17 was dependent on its LRRs, as truncation of 
this region weakened or ablated their interaction.
To test the directness of the interaction between Fbxl17 
and one of its interacting proteins, we performed a GST 
pull-down assay using Uap1. We tested GST-Fbxl17(321-
701aa), GST-Fbxl17Δ10LRR(321-383aa), and GST-Skp2, 
another LRR-containing FBP, and GST only were used 
as controls. GST-FBP proteins were co-expressed with 
an IRES-Skp1 to facilitate expression in bacteria, with 
the exception of Fbxl17Δ10LRR, which was robustly 
expressed. GST-FBPs were immobilised on a GST col-
umn and incubated with in vitro transcribed and translated 
Uap1. Following binding assays, samples were resolved 
by SDS-PAGE, and membranes probed with antibodies 
Table 1  Fbxl17 interacting proteins
Minimal region denotes the amino acids present in all interacting cDNA clones; full-length size is the predicted size of the protein. Ub denotes 
protein is ubiquitinated in [39]
Gene symbol Full name isolates Minimal region (aa) Full-length 
size (aa)
Modified
UAP1 UDP-N-acetylglucosamine pyrophosphorylase 1 26 357–505 505 Ub
UFC1 Ubiquitin-fold modifier conjugating enzyme 1 13 12–95 167 Ub
CSNK2B Casein kinase 2, beta polypeptide 4 1–123 215 Ub
KLHL12 Kelch-like 12 (Drosophila) 4 1–162 568
RLF Rearranged l-myc fusion 4 1670–1914 1914
C21orf91 EURL/Chromosome 21 open reading frame 91 4 1–178 296
ACSBG2 Acyl-CoA synthetase bubblegum family member 2 3 528–666 666
ETFA Electron-transfer-flavoprotein, alpha polypeptide 3 103–284 333 Ub
METAP2 Methionyl aminopeptidase 2 3 323–342 478 Ub
AKD1 Adenylate kinase domain containing 1 2 415–624 1911
SCG5 Secretogranin V (7B2 protein) 2 1–188 212
TASP1 Taspase, threonine aspartase, 1 2 135–318 420
KLHL7 Kelch-like 7 (Drosophila) 2 37–240 586 Ub
PHF7 PHD finger protein 7 1 50–236 381
ZMYM2 Zinc finger, MYM-type 2 1 141–390 1377
IDO1 Indoleamine 2,3-dioxygenase 1 1 14–128 403
PSME4 Proteasome (prosome, macropain) activator subunit 4 1 367–420 1843 Ub
PPP3CB Protein phosphatase 3, catalytic subunit, beta isozyme 1 381–496 524 Ub
ZNF350 Zinc finger protein 350 1 310–532 532
TGFBI Transforming growth factor, beta-induced, 68 kDa 1 115–326 683
SCPEP1 Serine carboxypeptidase 1 1 273–452 452 Ub
FILIP1L Filamin A interacting protein 1-like 1 508–705 1135
ACPL2 Acid phosphatase-like 2 1 266–464 480
TPP2 Tripeptidyl peptidase II 1 879–1141 1249 Ub
OLR1 Oxidized low density lipoprotein (lectin-like) receptor 1 1 124–273 273
USP25 Ubiquitin specific peptidase 25 1 323–450 1055 Ub
FAM190A Family with sequence similarity 190, member A 1 555–726 900
PCCB Propionyl CoA carboxylase, beta polypeptide 1 172–468 539
TMOD1 Tropomodulin 1 1 66–334 359
IFT46 Intraflagellar transport 46 homolog (Chlamydomonas) 1 1–216 304
SRBD1 S1 RNA binding domain 1 1 260–491 995
MED14 Mediator complex subunit 14 1 1053–1282 1454 Ub
CCDC147 Coiled-coil domain containing 147 1 478–684 872
HADH Hydroxyacyl-CoA dehydrogenase 1 112–261 261 Ub
CLPX ClpX caseinolytic peptidase × homolog (E. coli) 1 42–341 633
COG2 Component of oligomeric golgi complex 2 1 457–534 738 Ub
TMEM126A Transmembrane protein 126A 1 89–195 195 Ub
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to Uap1. We observed Uap1 binding specifically to GST-
Fbxl17(321-701aa), but not to GST only or to GST-Skp2. 
Moreover, deletion of 10 LRRs abolished Uap1 binding to 
Fbxl17 (Fig. 4a). These results indicate Fbxl17 interacts 
directly with Uap1, and this occurs via its LRRs.
Fbxl17 inhibits the phosphorylation of Uap1
To test the functional significance of Fbxl17 interaction 
with Uap1, we over-expressed Fbxl17 and monitored the 
steady state levels of Uap1 by immunoblotting. We found 
Uap1 levels were unchanged in the presence of MG132 or 
with increased levels of Fbxl17 (Fig. 4b), which suggests it 
does not promote the proteasomal degradation of Uap1. We 
next tested whether Uap1 was a substrate of  SCFFbxl17 ligase 
in vivo, by co-transfecting cells with HA-Uap1, Myc-ubiqui-
tin, and FLAG-Fbxl17 (WT or ∆F-box domain) constructs. 
However, we found no evidence of laddering or smearing 
of Uap1, indicative of its poly-ubiquitination. Instead, we 
detected a discrete, higher molecular weight species of Uap1 
upon transfection of Myc-ubiquitin (Fig. 4c, lane 2). More-
over, levels of this modified form of Uap1 were reduced 
when Fbxl17 was overexpressed (Fig. 4c, lane 5), indicat-
ing Fbxl17 opposed this modification of Uap1. Interestingly, 
this reduction of Uap1 modification was not observed when 
Fbxl17ΔFbox was overexpressed, (Fig. 4c, lane 6) suggest-
ing this effect was dependent on Skp1 binding and/or the 
ligase activity of Fbxl17.
To determine the type of modification this higher molecu-
lar weight species of Uap1 represented, we immunoblotted 
with antibodies to ubiquitin and to Myc-epitope tag (Myc-
ubiquitin). Surprisingly, these antibodies did not yield any 
signal in Uap1 immunoprecipitates, despite the overexpres-
sion of ubiquitin (S2C and S2D). These results indicated 
that the post-translational modification present on Uap1 was 
not ubiquitination. Based on the PhosphoSitePlus database, 
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Fig. 4  Fbxl17 inhibits the phosphorylation of UAP1. a In vitro GST 
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where multiple studies report Uap1 to be a phosphorylated 
protein, we tested whether this modified form of Uap1 rep-
resented a phosphorylated form. We conducted the in vivo 
ubiquitination assay in the presence of the phosphatase 
inhibitor β-glycerophosphate and alkaline phosphatase 
(CIP). Strikingly, the levels of modified Uap1 were almost 
completely absent following CIP treatment, suggesting the 
higher molecular weight species represented a phospho-
rylated form of Uap1 (Fig. 4d, lane 4). In sum, these data 
show that the overexpression of ubiquitin increases Uap1 
phosphorylation, and Fbxl17 overexpression prevents this 
modification, and this function is dependent on its FBD.
FBXL17 knockdown results in increased levels 
of O‑GlcNAcylation
Since Fbxl17 overexpression reduced the abundance of a 
phosphorylated Uap1, but not Uap1 steady state levels, we 
reasoned Fbxl17 might regulate Uap1 activity. Uap1 cataly-
ses the formation of UDP-N-acetylglucosamine (UDP-Glc-
NAc), which is used by the glycosyltransferase O-GlcNAc 
Transferase (OGT) to add N-acetylglucosamine in O-glyco-
sidic linkages to nuclear and cytosolic proteins. UAP1 is the 
main enzyme synthesizing UDP-GlcNAc [30–34]. Since our 
results indicate Fbxl17 opposes Uap1 phosphorylation, we 
tested whether reducing Fbxl17 expression would affect the 
amount of UDP-GlcNAc in the cell. U2OS cells were trans-
fected with an siRNA targeting Fbxl17 (Fig. S4B), metabo-
lites were extracted from these cells and UDP-GlcNAc lev-
els were determined by mass spectrometry. We observed a 
36% decrease (p = 0.013; n = 5) in total UDP-GlcNAc levels 
in Fbxl17 knockdown cells (Fig. 4e), which suggests that 
Fbxl17 promotes Uap1 activity.
To determine the downstream effects of Fbxl17 on 
this pathway, we next tested the effect of reduced Fbxl17 
expression on the levels of O-GlcNAc modified cellular 
proteins. U2OS cells were treated with Fbxl17 siRNA as 
above, and cell lysates were immunoblotted for O-GlcNAc. 
Although UDP-GlcNAc levels were reduced in Fbxl17 KD 
cells (Fig. 4e), we observed increased levels of O-GlcNAc-
modified proteins in Fbxl17 knockdown cells (Fig. 5a). This 
was also shown in two breast cell lines, HB4a and MCF7, by 
expression of shRNA constructs targeting FBXL17 expres-
sion (Figs. 5b, c; S4C). This increase in O-GlcNAc modified 
proteins, despite reduced levels of UDP-GlcNAc, may be a 
result of changes in the expression or activity of the enzymes 
responsible for adding or removing O-GlcNAc, namely Ogt 
and Oga, which act downstream of Uap1 and UDP-GlcNAc. 
We therefore determined whether Ogt and Oga were changed 
following knockdown of Fbxl17. Although Ogt levels were 
unchanged, Oga levels were reduced which suggests the 
increased O-GlcNAcylated proteins is due to decreased 
Oga levels (Fig. 5d). Consistent with reduced Oga levels, 
mass spectrometry analysis of levels of GlcNAc, the product 
of Oga-mediated cleavage of O-GlcNAc modifications from 
proteins, were reduced by 18%, although this was not signifi-
cant, in cells treated with Fbxl17 siRNA (Fig. 5e). Finally, 
we surveyed the expression of Fbxl17 and Uap1 expression 
in breast cancer datasets using the R2 platform (http://www.
r2.amc.nl). Kaplan–Meier analysis for these genes revealed 
that breast tumours with either low Fbxl17 expression, or 
high Uap1 expression were associated with poorer survival 
in patients (Fig. S5).
Discussion
Our results collectively indicate that FBXL17 is frequently 
mutated in epithelial cancers in the genomic regions encod-
ing its LRRs. We found FBXL17 was rearranged in around 
7% of breast cancers according to array-CGH, and also in 
cancer cell lines. Independently, analysis of sequence-level 
mutation data also suggested that FBXL17 behaves like a 
tumour suppressor gene [35]. Many point mutations and 
breaks in FBXL17 occurred in regions encoding its LRRs. 
These motifs are proposed to be the substrate docking sites 
within FBXL proteins, and are predicted to cause a failure 
to recruit substrates. Indeed, we find that progressive dele-
tion of its LRRs caused decreased auto-ubiquitination and 
ubiquitination of a substrate, Sufu, by  SCFFbxl17. However, 
we also discovered that deleting LRRs impaired the assem-
bly of the E3 ubiquitin-ligase complex. Both of the Fbxl17 
LRR truncation mutants, ∆3LRR and ∆10LRR, bound Skp1 
less well compared to WT, despite them containing the Skp1 
binding motif. Reduced interactions with Cul1 and Rbx1 are 
likely due to less Skp1 binding, since FBPs do not interact 
directly with Cul1 or Rbx1 [36]. The C-terminus of an FBP 
has been shown in specific cases to contact Skp1 to stabilise 
the ligase [36], and our data show that truncating the LRRs 
of Fbxl17 also destabilises the SCF ligase. We predict that 
even if a truncated Fbxl17 were able to recruit some of its 
substrates, it would be less efficient in ubiquitinating them. 
Thus in the context of breast cancer, the rearrangements that 
target the LRRs of FBXL17 would likely diminish ubiquit-
ination of the network of  SCFFbxl17 substrates.
To investigate functional consequences of these rear-
rangements, we screened for proteins interacting with the 
LRR of Fbxl17. Our yeast two-hybrid screen identified 
37 novel interactions, which was found to only minimally 
overlap with previous studies reporting Fbxl17 interact-
ing proteins [37, 38]. Only eight proteins, Klhl12, Klhl7, 
Zmym2, Hadh, Clpx, Ppp3cb, Pccb, Srbd1 also appeared in 
these other studies. However, Uap1 and Ufc1, the most fre-
quently recovered cDNAs in our screen, were not identified 
by either. The varied findings by different screening meth-
odologies, indicates they identify distinct partner proteins 
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and argues for a variety of experimental approaches to dis-
covering protein interaction networks. Screens for interact-
ing partners may identify substrates or regulators of FBPs. 
When validating four of the most repeatedly isolated prey 
cDNAs in mammalian cells, we noted differential binding 
(Csnk2B > Uap1 > Ufc1 > Klhl12) depending on the deletion 
of 3 or 10 LRRs. Notably, the Casein Kinase 2 subunit, 
Csnk2B, remained bound to Fbxl17 after deletion of 10 
LRRs, suggesting that it binds to another region of Fbxl17, 
or other E3 ubiquitin ligase components, and may be a reg-
ulator of the ligase. Among the other interactors, Fbxl17 
binding to Klhl12 or Ufc1 was decreased when the last three 
Fig. 5  Knockdown of Fbxl17 
increases total O-GlcNAcyla-
tion. a U2OS cells treated with 
Fbxl17 siRNA3 or control 
siRNA for 48 h followed by 
PugNAc treatment, 50 µM 3 h. 
Whole cell lysates immunoblot-
ted with the indicated antibod-
ies, n = 2. b FBXL17 mRNA 
knockdown by shRNA in HB4a 
immortalised normal breast 
cells (bottom panel). Expression 
normalised to GAPDH and plot-
ted relative to miR30-infected 
control cells. Mean ± SEM 
of at least three independent 
experiments. O-GlcNAcylation 
monitored by immunoblotting 
with anti-O-GlcNAc antibodies 
(top panel). c FBXL17 mRNA 
knockdown by shRNA in MCF7 
breast cancer cells (bottom 
panel). Expression normal-
ised to scRNA-infected cells. 
Mean ± SEM of at least three 
independent experiments. Total 
O-GlcNAcylation monitored 
by immunoblotting with anti-
O-GlcNAc antibodies. + and 
++, 25 or 50 μg of protein 
lysate (top panel). d U2OS cells 
treated with Fbxl17 siRNA3 or 
control siRNA for 48 h. Whole 
cell lysates immunoblotted 
with the indicated antibodies. 
Band intensities quantified by 
densitometry and normalised 
to GAPDH expression (values 
below blots), n = 3. e LC–MS 
analysis of total GlcNAc levels 
in U2OS cells treated with 
Fbxl17 siRNA3 or control 
siRNA for 48 h. Mean ± SEM 
for five biological replicates. f 
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LRRs were truncated. However, Uap1 binding was disrupted 
only when ten LRRs were truncated suggesting Uap1 can 
bind to LRR2-8. These data led us to a model whereby the 
number of LRRs in Fbxl17, as dictated by the position of a 
rearrangement within FBXL17, would influence its interac-
tion with its repertoire of partners. However, due to inef-
ficient ligase assembly by LRR-truncated Fbxl17 mutants, 
we predict the ubiquitination of these proteins would be 
diminished. We note that 15 of the 37 proteins identified 
in the yeast two-hybrid screen are listed as being ubiquit-
inated proteins in a whole proteomic analysis of HEK293 
cells (Table 1) [39].
There are not yet enough data on rearrangement of 
FBXL17 in cancers to conclusively identify FBXL17 inacti-
vation as a driver mutation in cancer. Nonetheless, we were 
able to show a striking effect of reducing Fbxl17 expression 
on at least one important cancer-relevant pathway, in a rel-
evant cell type, suggesting that inactivation of Fbxl17 would 
have a major effect on the cancer cell. This was through 
its regulation of Uap1, which is expressed in many breast 
cancers (Figs. S4D, S5D) and other cancer types [34, 40]. 
Surprisingly, we did not find Uap1 to be ubiquitinated by 
Fbxl17, but instead our results showed that increased Fbxl17 
expression prevented the phosphorylation of Uap1. In addi-
tion, this inhibition of Uap1 phosphorylation was depend-
ent on the Skp1-binding domain of Fbxl17, suggesting that 
 SCFFbxl17 ligase activity is essential. In contrast to Ogt and 
Oga [41], little is known about the regulation of Uap1, and 
our data suggest Fbxl17 positively regulates its activity 
(Fig. 5f). UDP-GlcNAc levels are significantly decreased 
when Fbxl17 is knocked down suggesting reduced Uap1 
activity which is consistent with previous studies showing 
Uap1 expression is important for UDP-GlcNAc levels [34]. 
Although we have not identified the kinase responsible for 
phosphorylating Uap1, one possibility is that Fbxl17 ubiqui-
tinates this kinase to inhibit its phosphorylation of Uap1 and 
promote Uap1 activity. Alternatively, Fbxl17 could shield 
Uap1 from this kinase, via a direct interaction between 
Fbxl17 and Uap1 (Figs. 4a, 5f).
We have shown that Fbxl17 regulates the O-GlcNAcyla-
tion pathway since reducing FBXL17 expression in three 
cell lines increased global levels of O-GlcNAc-modified pro-
teins. We did not assess glycosylation in the ER or Golgi, 
so cannot rule out a specific role for Fbxl17 there. How-
ever, the increase in global O-GlcNAcylation may be the 
result of greater utilisation of UDP-GlcNAc by Ogt, which 
would explain the lower UDP-GlcNAc levels and higher 
O-GlcNAcylation we observed in Fbxl17 knockdown cells. 
Although Ogt expression levels were unchanged, we cannot 
rule out that its activity is increased when Fbxl17 levels are 
reduced. However, the higher levels of O-GlcNAc modi-
fied proteins are likely due to the observed decrease in Oga 
expression. It has been proposed that there is an optimal 
level of global O-GlcNAcylation levels for cells to func-
tion and this is maintained by mutual regulation and balance 
of Ogt/Oga expression and activity [41, 42]. The decrease 
in Oga expression may represent a compensatory mecha-
nism adopted by the cell to counteract the decrease in Uap1 
activity and UDP-GlcNAc levels. O-GlcNAcylation is an 
important post-translational modification on many intra-
cellular proteins—including p53, RNA polymerase II, the 
polycomb complex and Phosphofructokinase 1 (Pfk1), the 
main regulator of glycolysis—and is essential for viability 
of several mammalian cell types [43, 44]. Moreover, there 
is already considerable evidence that GlcNAcylation is 
altered in breast cancer and other cancers [45–48]. Cald-
well et al. [49] found that breast cancer cells had increased 
O-GlcNAcylation and elevated OGT. Knocking down OGT 
inhibited tumour growth, decreased cell cycle progression, 
increased expression of the cell cycle inhibitor p27Kip1, and 
decreased invasiveness [49]. High nuclear and cytoplasmic 
O-GlcNAc was also observed in breast cancer patients with 
increased relapse rates, increased sites of distant metastases 
and poor outcome [50]. In breast cancer, low OGA levels 
are linked to higher grade tumours and metastasis [51]. We 
have shown that the regulation of Uap1 by Fbxl17 and an 
unidentified kinase, are factors in determining the levels of 
the O-GlcNAcylated proteome.
In conclusion, by surveying structural rearrangements in 
cancer databases, we discovered rearrangements commonly 
occur in FBXL17 which affect its ability to bind substrates 
and also assemble as part of a functional SCF ubiquitin 
ligase complex. By screening for Fbxl17 interacting pro-
teins, we discovered Uap1 as a binding partner, but not a 
substrate of Fbxl17, and established that Fbxl17 is a negative 
regulator of global O-linked GlcNAcylation. The loss-of-
function mutations in FBXL17 caused by structural rear-
rangements could have additional effects on the cell, since 
the targets of Fbxl17 are involved in major, cancer-relevant 
cellular processes.
Materials and methods
Yeast two‑hybrid assay
The matchmaker gold yeast two-hybrid system (Clontech) 
was used to screen a human cDNA library (Mate & Plate™ 
Library—Normalized, Universal Human (Clontech)). 
Fbxl17 aa 321 to 701 was PCR amplified and subcloned 
into pGBKT7 (Clontech). aa 321 to 586 was amplified from 
pGBKT7-FBXL17 plasmid and subcloned into pGBKT7 to 
create the (∆3LRR) bait construct.
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Purification of  SCFFbxl17 complexes
HEK293T cells were transfected with SCF components 
(Skp1, Cul1, Myc-Rbx1) and FLAG-Fbxl17 constructs. 
After 48 h, cells were resuspended in lysis buffer (LB) 
(25 mM Tris–HCl, pH 7.5, 225 mM KCl, 1% NP-40) with a 
protease inhibitor cocktail (Sigma-Aldrich) and phosphatase 
inhibitors (10 mM NaF, 1 mM PMSF, 1 mM  Na3VO4). 
Lysates were incubated with Anti-FLAG® M2 Affinity 
Gel (Sigma-Aldrich) for 5 h at 4 °C with rotation. Beads 
were washed in LB and eluted in 300 µg/mL FLAG peptide 
(Sigma-Aldrich) in elution buffer (10 mM HEPES, pH 7.9, 
225 mM KCl, 1.5 mM  MgCl2, 0.1% NP-40) for 1 h at 4 °C 
with rotation. Purified SCF complexes were stored in 15% 
glycerol.
In vitro ubiquitination assays
A screen of 10 different E2 enzymes determined that E2 
UbcH5a enabled the most specific  SCFFbxl17 activity and 
was used in subsequent experiments. Purified SCF com-
plexes at 12.5, 25, 50 and 100 nM were tested in the pres-
ence of a ubiquitin-mix (ubiquitin buffer, ubiquitin (20 µM) 
E1 (UBE1, 100 nM), E2 (UbcH5a, 500 nM) and Mg-ATP 
(2 mM) (Boston Biochem)) incubated at 30 °C for 90 min 
to determine ligase activity by auto ubiquitination. 50 nM 
of the SCF was sufficient for ligase activity and used in sub-
sequent experiments. To test substrate ubiquitination sub-
strates were transfected into HEK293T cells and immuno-
precipitated using their indicated epitope tags conjugated to 
agarose beads. The purified substrate was then eluted from 
the beads and added as a component of the ubiquitin-mix. 
HA-Sufu was kindly provided by Vincenzo D’Angiolella 
(CRUK/MRC Oxford Institute for Radiation Oncology, 
Oxford, UK). Ubiquitination was detected by probing for 
the substrate or HA tag.
In vivo ubiquitination assays
HEK293T cells were transfected with expression constructs 
of interest, including myc-ubiquitin, and treated with 10 µM 
MG132 (Sigma-Aldrich) 5 h prior to lysis. UAP1 was then 
immunoprecipitated with Monoclonal Anti-HA-Agarose 
antibody (Sigma-Aldrich). Modified UAP1 was detected 
with an endogenous UAP1 antibody. To test for phospho-
rylation 10 mM β-glycerophosphate or alkaline phosphatase 
(CIP) was added to the LB where indicated. LB containing 
CIP did not contain phosphatase inhibitors (NaF,  Na3VO4).
DNA constructs
Coordinates and exon numbers for the FBXL17 gene are 
from Ensembl transcript ENST00000542267.5 (Fig. 1). 
Human FBXL17 cDNA (GenScript) was subcloned into 
pcDNA3 and pcDNA3-FLAG. Truncation (∆3LRR) 
and (∆10LRR) and deletion constructs (ΔFbox) were 
constructed by amplification or two-step PCR mutagen-
esis. Human Ufc1 and Uap1 cDNAs were obtained from 
GeneArt. pcDNA3.1-FLAG-hKLHL12 was kindly provided 
by S. Angers (University of Toronto, Canada). pCK2_
V2N1_Venus2-HA-CSNK2B_N1 was kindly provided by 
A. Beck-Sickinger (Leipzig University, Germany).
Antibodies
The following antibodies were purchased anti-β-actin 
(Abcam, ab8227), anti-Cul1 (Santa Cruz, sc-11384), anti-
Fbxl17 (Genetex, GTX119211), anti-FLAG® M2 (Sigma-
Aldrich, F3165), anti-Gal4 DBD (Santa Cruz, sc-510), 
anti-GAPDH (Sigma, G9545), anti-HA (Abcam, ab9110), 
anti-HA (C29F4) (Cell Signalling, 3724S), anti-Histone 
H1 (Santa Cruz, sc-8030), anti-Klhl12 (Abcam, ab14233), 
anti-myc tag (Cell Signalling, 2272), anti-O-GlcNAc (Cov-
ance, MMS-248R), anti-p19 (Skp1) (BD Biosciences, 
610530), anti-UAP1 (Abcam, ab95949), anti-Ub (Santa 
Cruz, sc-8017), HRP-conjugated antibodies to mouse or 
rabbit IgG (Santa Cruz Biotechnology, sc-2055, sc-2313) 
or chicken IgY (Abcam, ab97135), Donkey anti-Rabbit and 
anti-Mouse IgG conjugated to Alexa Fluor 488 (Invitro-
gen). Signal detection was by enhanced chemiluminescence 
(ECL) (GE Healthcare).
Cell culture, plasmids and transfection
HB4a is an immortalised normal breast epithelial cell 
line from M.J. O’Hare [52]. Cell lines were maintained 
in DMEM supplemented with 10% foetal bovine serum 
(ThermoFisher), 2 mM glutamine, 100 U/mL penicillin and 
streptomycin at 37 °C in a humidified 5%  CO2 atmosphere. 
Where indicated, cells were treated with (50 µM) PugNAc, 
an inhibitor of O-GlcNAc-β-N-acetylglucosaminidase (Oga), 
for 3 h prior to cell lysis.
Immunoblotting and immunoprecipitation analysis
Cells were lysed in protein extraction buffer (20  mM 
Tris–HCl pH 7.4, 1% IGEPAL, 1% Triton X-100, 50 mM 
NaCl, 2 mM EDTA pH 8, 30 mM  NaP2O7 and protease 
inhibitor cocktail (Roche)). For the analysis of O-Glc-
NAcylated proteins, cells were lysed in RIPA buffer plus 
protease inhibitors.
For immunoprecipitation (IP) experiments, cells were 
lysed in hypotonic lysis buffer (10 mM Tris–HCl pH 7.5, 
10 mM NaCl, 2 mM EDTA, 0.5% Triton X-100 and protease 
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inhibitors) and immunoprecipitated with agarose-anti-HA 
(Sigma) or agarose-anti-FLAG (Anti-FLAG® M2 Affin-
ity Gel, Sigma-Aldrich) for 3.5 h. Beads were pelleted 
and washed four times in 1 × NET2 wash buffer (50 mM 
Tris–HCl pH7.5, 150 mM NaCl, 0.05% Triton X-100). 
Bound proteins were eluted by addition of 40 µL 2 × Lae-
mmli sample buffer and incubation at 60 °C for 3 min.
siRNA and shRNA expression
siRNAs were purchased from Eurofins genomics and 
transfected at a final concentration of ~ 60 nM using Lipo-
fectamine™ RNAiMAX (ThermoFisher). Sequences for the 
siRNAs were as follows:
siRNA2: GCA GAG AAC TCA AAG ATA T
siRNA3: GGA CAA ACT CAC TGA TGA A
4 × 106 ψNx cells were calcium phosphate transfected 
with shRNA or scRNA retroviral expression constructs with 
25 μM chloroquine (Sigma-Aldrich). 2 days post-transfec-
tion, 2 × 106 of target cells were infected with retroviruses 
in the presence of polybrene (Sigma-Aldrich).
Sequences for the shRNAs were as follows:
shRNA 1: GGA CAA ACT CAC TGA TGA AGG (targets 
exon 3 of FBXL17);
shRNA 2: GCT TGG ACC TAC GTC ATA TCA (targets 
exon 6 of FBXL17);
shRNA 3: AGG CAT GAT CGT CAT AGC TAA (targets 
exon 4 of FBXL17).
The following day, cells were selected using 1.7 μg/mL 
of puromycin. After selection, RNA was extracted, reverse 
transcribed and quantified by qPCR. Expression level was 
normalised to GAPDH expression and was plotted rela-
tive to the expression of FBXL17 in the relevant control. 
Values represent mean ± SEM of at least three independent 
experiments.
Metabolites extraction and LC–MS analysis
Cells were washed three times with PBS prior the extraction 
and 1 ml of extraction buffer (50% LC–MS grade methanol 
and 30% acetonitrile, 20% ultrapure water) was added per 
1 × 106 cells. Cell were then incubated on dry ice for 15 min, 
collected, kept under vigorous shaking for 15 min at 4 °C, 
and left for 1 h incubation at 20 °C. Samples were centri-
fuged at 13,000 rpm and supernatants were transferred to 
autosampler vials for LC–MS analysis. To avoid bias due 
to machine drift and processed blindly, samples were rand-
omized. Q Exactive mass spectrometer (Thermo Fisher Sci-
entific) coupled to a Dionex U3000 UHPLC (Thermo Fisher 
Scientific) system was used to perform the LC–MS analysis. 
Sequant ZIC-pHILIC column (150mm 3 2.1 mm) and guard 
column (20 mm 3 2.1 mm) (Merck Millipore) were utilized 
for the chromatographic separation and the column oven 
temperature was maintained at 40 °C. The mobile phase 
was composed of 20 mM ammonium carbonate and 0.1% 
ammonium hydroxide in water (solvent A), and acetonitrile 
(solvent B). The flow rate was set at 200 mL/min with the 
gradient was programmed as follows: initially stayed at 20% 
of A and 80% of B for 2 min, then subjected to a linear 
increase to 80% of A and decrease to 20% of B in 15 min. 
Both solvents were then brought back to initial condition and 
staid for 8 min. The mass spectrometer was operated in full 
MS and tSIM (targeted Single Ion Monitoring), in positive 
and negative mode. XCalibur Qual Browser and XCalibur 
Quan Browser software (Thermo Fisher Scientific) were 
used to acquire the spectra and analyse the data.
Quantitative PCR
All qPCR reactions were performed in triplicates using 
 LightCycler® 480 SYBR Green Master Mix (Roche) accord-
ing to manufacturer’s instructions. The relative expression 
ratio of a target gene in comparison to a reference gene in a 
cDNA panel was quantified [53]. GAPDH was used as an 
endogenous housekeeping transcript. The relative expres-
sion level was based on the difference in Ct values between 
a control cell line such as HB4a and a sample cell line in the 
cDNA panel.
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